Re-evaluating Criteria for Accelerated Approval
نویسنده
چکیده
Conference on Clinical Cancer Research November 2012 Re-evaluating Criteria for Accelerated Approval Richard L. Schilsky, Chief, Section of Hematology-Oncology, University of Chicago Medical Center David P. Schenkein, CEO, Agios Pharmaceuticals Wyndham H. Wilson, Senior Investigator, Chief, Lymphoma Therapeutics Section, NCI Cheryl L. Jernigan, Research/Patient Advocate, Susan G. Komen for the Cure Janet Woodcock, Director, CDER, FDA
منابع مشابه
Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.
Policy Points: Randomized trials-the gold standard of evaluating effectiveness-constitute a small minority of existing evidence on agents given accelerated approval. One-third of randomized trials are in therapeutic areas outside of FDA approval and less than half evaluate the therapeutic benefits of these agents but use them instead as common backbone treatments. Agents receiving accelerated a...
متن کاملThe potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases
BACKGROUND Over 95% of rare diseases lack treatments despite many successful treatment studies in animal models. To improve access to treatments, the Accelerated Approval (AA) regulations were implemented allowing the use of surrogate endpoints to achieve drug approval and accelerate development of life-saving therapies. Many rare diseases have not utilized AA due to the difficulty in gaining a...
متن کاملEvaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.
BACKGROUND In metastatic renal cell cancer (mRCC) trials, progression-free survival (PFS) is increasingly used instead of overall survival (OS) as the approval end point. Unlike other solid tumors, there is no published demonstration of what PFS is needed across and by treatment class in mRCC. We determine this and evaluate drug approval decisions in mRCC targeted therapy. METHODS We identifi...
متن کاملAccelerated approval of oncology products: the food and drug administration experience.
We reviewed the regulatory history of the accelerated approval process and the US Food and Drug Administration (FDA) experience with accelerated approval of oncology products from its initiation in December 11, 1992, to July 1, 2010. The accelerated approval regulations allowed accelerated approval of products to treat serious or life-threatening diseases based on surrogate endpoints that are r...
متن کاملReevaluating the accelerated approval process for oncology drugs.
For a new therapy to qualify for the accelerated approval pathway, it must treat a serious disease for which there is "unmet medical need"--defined as providing a therapy where none exists or providing a therapy that may be potentially superior to existing therapy. The increasing number of available therapies, coupled with the lack of accepted endpoints considered "reasonably likely to predict ...
متن کامل